Lombard Odier Asset Management Switzerland SA reduced its position in CVS Health Co. (NYSE:CVS – Free Report) by 88.9% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,496 shares of the pharmacy operator’s stock after selling 99,638 shares during the period. Lombard Odier Asset Management Switzerland SA’s holdings in CVS Health were worth $864,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Weik Capital Management increased its holdings in shares of CVS Health by 0.7% during the first quarter. Weik Capital Management now owns 17,600 shares of the pharmacy operator’s stock worth $1,781,000 after buying an additional 120 shares in the last quarter. FCA Corp TX increased its holdings in shares of CVS Health by 0.6% during the first quarter. FCA Corp TX now owns 20,109 shares of the pharmacy operator’s stock worth $2,035,000 after buying an additional 122 shares in the last quarter. Arvest Trust Co. N A increased its holdings in shares of CVS Health by 1.2% during the fourth quarter. Arvest Trust Co. N A now owns 11,157 shares of the pharmacy operator’s stock worth $1,040,000 after buying an additional 131 shares in the last quarter. Ten Capital Wealth Advisors LLC increased its holdings in shares of CVS Health by 8.4% during the second quarter. Ten Capital Wealth Advisors LLC now owns 1,787 shares of the pharmacy operator’s stock worth $123,000 after buying an additional 138 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. increased its holdings in shares of CVS Health by 0.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 29,160 shares of the pharmacy operator’s stock worth $2,016,000 after buying an additional 141 shares in the last quarter. 75.99% of the stock is owned by hedge funds and other institutional investors.

CVS Health Trading Up 0.8 %

Shares of NYSE CVS traded up $0.53 during midday trading on Friday, reaching $68.48. 7,094,672 shares of the stock were exchanged, compared to its average volume of 6,100,314. The business has a 50-day simple moving average of $69.43 and a two-hundred day simple moving average of $69.93. The company has a market capitalization of $88.13 billion, a price-to-earnings ratio of 10.33, a P/E/G ratio of 1.77 and a beta of 0.54. CVS Health Co. has a 12 month low of $64.41 and a 12 month high of $104.83. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.86 and a quick ratio of 0.64.

CVS Health (NYSE:CVS – Get Free Report) last announced its quarterly earnings results on Wednesday, November 1st. The pharmacy operator reported $2.21 earnings per share for the quarter, topping analysts’ consensus estimates of $2.13 by $0.08. CVS Health had a net margin of 2.47% and a return on equity of 15.36%. The company had revenue of $89.76 billion for the quarter, compared to analysts’ expectations of $88.29 billion. During the same period last year, the firm posted $2.09 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. As a group, equities research analysts expect that CVS Health Co. will post 8.59 EPS for the current year.

CVS Health Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Investors of record on Friday, October 20th were issued a dividend of $0.605 per share. The ex-dividend date of this dividend was Thursday, October 19th. This represents a $2.42 dividend on an annualized basis and a dividend yield of 3.53%. CVS Health’s payout ratio is 36.50%.

Insider Buying and Selling

In related news, Director Edward J. Ludwig acquired 2,000 shares of the company’s stock in a transaction that occurred on Friday, November 3rd. The shares were acquired at an average cost of $70.47 per share, for a total transaction of $140,940.00. Following the completion of the acquisition, the director now directly owns 20,630 shares in the company, valued at approximately $1,453,796.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.25% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CVS. Morgan Stanley decreased their price target on shares of CVS Health from $110.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. Royal Bank of Canada decreased their price target on shares of CVS Health from $91.00 to $86.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Raymond James decreased their price target on shares of CVS Health from $90.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, August 4th. Evercore ISI raised shares of CVS Health from an “in-line” rating to an “outperform” rating and increased their price target for the company from $81.00 to $83.00 in a research note on Tuesday, September 19th. Finally, TheStreet raised shares of CVS Health from a “c” rating to a “b-” rating in a research note on Wednesday, November 1st. Four equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, CVS Health has an average rating of “Moderate Buy” and a consensus target price of $92.59.

Check Out Our Latest Research Report on CVS

CVS Health Company Profile

(Free Report)

CVS Health Corporation provides health services in the United States. It operates through Health Care Benefits, Pharmacy Services, and Retail/LTC segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider CVS Health, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and CVS Health wasn’t on the list.

While CVS Health currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here